Cash Flow Statement

The cash flow statement provides information about a company cash receipts and cash payments during an accounting period, showing how these cash flows link the ending cash balance to the beginning balance shown on the company balance sheet.

The cash flow statement consists of three parts: cash flows provided by (used in) operating activities, cash flows provided by (used in) investing activities, and cash flows provided by (used in) financing activities.

Abbott Laboratories, consolidated cash flow statement

US$ in millions

12 months ended:	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Net earnings	5,723)	6,933)	7,071)	4,495)	3,687)
Depreciation	1,277)	1,254)	1,491)	1,195)	1,078)
Amortization of intangible assets	1,966)	2,013)	2,047)	2,132)	1,936)
Share-based compensation	644)	685)	640)	546)	519)
Investing and financing losses, net	126)	215)	55)	425)	184)
Loss on extinguishment of debt	—)	—)	—)	—)	63)
Trade receivables	(356)	(68)	(383)	(924)	(275)
Inventories	(232)	(1,413)	(456)	(493)	(593)
Prepaid expenses and other assets	(542)	(75)	(312)	(627)	(138)
Trade accounts payable and other liabilities	(760)	420)	1,288)	1,766)	220)
Income taxes	(585)	(383)	(908)	(614)	(545)
(Increase) decrease in operating capital	(2,475)	(1,519)	(771)	(892)	(1,331)
Adjustments to reconcile earnings to net cash from operating activities	1,538)	2,648)	3,462)	3,406)	2,449)
Net cash from operating activities	7,261)	9,581)	10,533)	7,901)	6,136)
Acquisitions of property and equipment	(2,202)	(1,777)	(1,885)	(2,177)	(1,638)
Acquisitions of businesses and technologies, net of cash acquired	(877)	—)	(187)	(42)	(170)
Proceeds from business dispositions	40)	48)	134)	58)	48)
Purchases of investment securities	(159)	(185)	(173)	(83)	(103)
Proceeds from sales of investment securities	43)	152)	77)	10)	21)
Other	22)	22)	26)	19)	27)
Net cash used in investing activities	(3,133)	(1,740)	(2,008)	(2,215)	(1,815)
Proceeds from issuance (repayments) of short-term debt, net and other	21)	47)	(204)	2)	—)
Proceeds from issuance of long-term debt and debt with maturities over 3 months	2)	7)	4)	1,281)	1,842)
Repayments of long-term debt and debt with maturities over 3 months	(2,498)	(753)	(48)	(1,333)	(3,441)
Purchases of common shares	(1,227)	(3,795)	(2,299)	(403)	(718)
Proceeds from stock options exercised	167)	167)	255)	245)	298)
Dividends paid	(3,556)	(3,309)	(3,202)	(2,560)	(2,270)
Other	—)	—)	—)	(11)	—)
Net cash used in financing activities	(7,091)	(7,636)	(5,494)	(2,779)	(4,289)
Effect of exchange rate changes on cash and cash equivalents	(23)	(122)	(70)	71)	(16)
Net increase (decrease) in cash and cash equivalents	(2,986)	83)	2,961)	2,978)	16)
Cash and cash equivalents, beginning of year	9,882)	9,799)	6,838)	3,860)	3,844)
Cash and cash equivalents, end of year	6,896)	9,882)	9,799)	6,838)	3,860)

Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).

Download chart

Cash flow statement item	Description	The company
Net cash from operating activities	Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.	Abbott Laboratories net cash from operating activities decreased from 2021 to 2022 and from 2022 to 2023.
Net cash used in investing activities	Amount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.	Abbott Laboratories net cash used in investing activities increased from 2021 to 2022 but then decreased significantly from 2022 to 2023.
Net cash used in financing activities	Amount of cash inflow (outflow) of financing activities, excluding discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.	Abbott Laboratories net cash used in financing activities decreased from 2021 to 2022 but then slightly increased from 2022 to 2023.

Abbott Laboratories (NYSE:ABT)

Cash Flow Statement